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Abstract 
Human Papillomaviruses can cause cancer of multiple human anatomical sites, with essentially 
all cervical cancer cases worldwide being attributable to persistent HPV infections. HPV 
vaccination provides effective protection against HPV infections. An estimated 90% of cervical 
cancer cases occur in low and middle incomes, but only 20% of these countries have 
implemented HPV vaccination. In contrast, 82% of high income countries have included HPVV 
in their national vaccination programs. Current HPV vaccination schedules which recommend 
administering multiple doses within six months can be logistically challenging for both low- and 
middle-income as well as high-income countries. The ongoing global shortage of HPV vaccines 
that is expected to last until 2024 is an additional challenge. There are suggestions to extend the 
two dose 0,6 months schedule for the primary target population (females 9-14 years) to longer 
intervals, even up to 3-5 years, to ease logistics and relieve demand in the short-term. Interval 
extension however, requires evidence to support whether it will be beneficial. This paper reports 
findings of a systematic review of available studies, that compares the immunogenicity, efficacy 
and effectiveness of two-dose schedules of 7 or more months between doses with schedules of 6 
months between doses. We found, similar to a previous systematic review, that increasing the 
two-dose interval from 6 months to 12 months resulted in non-inferior immunogenicity. Also an 
increase of the dose-interval from 6 months to 36-96 months, results in non-inferior antibody 
response to HPV6 and high risk HPV types 16 and 18, but not HPV11, based on data from an 
observational study. The effect of an interval of 8 or more months compared to an interval of 4-7 
months on AGW incidence was inconclusive and no studies were available to assess efficacy or 
effectiveness against HPV infections or cancers. This highlights the acute scarcity of evidence 
necessary to evaluate two-dose schedules with intervals longer than 6 months. Nevertheless, our 
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non-inferiority findings indicate that a schedule with a 12 month interval can be adopted in lieu 
of one with a 6 month interval. However, even though the 36-96 month interval is indicated to be 
no worse than a 6 month interval in antibody response to HPV 16 and 18, the low certainty of the  
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Introduction to the Public Health Problem 
The Human Papillomavirus (HPV) is the most common sexually transmitted infection globally1,2 
and the leading viral cause of cancers worldwide3,4. HPV is a risk factor for multiple cancers, 
accounting for an estimated 29.5% of infection-related cancers worldwide4 and an even greater 
proportion (54%) of infection-related cancers in Canada5. There are over 100 genetic types of 
HPV, of which 14 are qualified as high-risk HPV (hrHPV) types based on their oncogenic 
potential. Persistent infection with HPV types 16 and 18 are associated with over 70% of cervical 
cancer cases, and together with HPV types 31, 33, 45, 52, 58, account for approximately 90% of 
cancers of the cervix3. HPV infections are also associated with non-cervical cancers, including 
anal, penile, vaginal, vulvar and oropharyngeal cancers2,3,5. HPV types 6 and 11 are low-risk HPV 
types, however they cause over 90% of ano-genital warts (AGWs)2,6. Although non-malignant, 
AGWs can cause discomfort, negative psychosocial effects and substantial direct treatment costs 
in many populations7–11.  
Women bear a predominant share of the global HPV-related cancer burden, due to cervical cancer 
having the highest prevalence and mortality of all HPV-related cancers2,3. In 2018, all 570,000 
new cervical cancer cases worldwide were attributable to HPV infection3. HPV-related cancer 
burden is greatest for women in developing and least developed countries (human development 
index <0.8) with approximately 88% cervical cancer deaths occurring among women in these 
countries12.   
HPV vaccines (HPVVs) have delivered significant reductions in HPV infections and associated 
morbidities in countries that have implemented HPV vaccination programs13–16. Meta-analysis of 
data from fourteen such high-income countries showed that after 5-9 years of HPV vaccination, 
these countries achieved significant reductions in the prevalence of hrHPV types 16, 18, 31, 33 
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and 45 among women. Highest reductions between the pre-vaccination and post-vaccination 
periods in these countries were seen for younger women 13-18 years, with the prevalence of 
HPV16 and 18 reduced by as much as 83%14. Significant reductions in cervical intraepithelial 
neoplasia grade 2 or higher (CIN2+; a pre-invasive pre-cursor to cervical cancer) and AGWs were 
also seen. These effects were greatest among women 15-19 years (51% reduction for CIN2+ and 
67% reduction of AGWs)14. With vaccinated females being protected against HPV infection, 
males were less likely to be exposed to the virus during female sexual contact. The population 
level benefits of HPV vaccination among women were therefore extended to males through herd 
effects. This was observed as significant decreases in AGW diagnoses among men 15-24 years, 
with estimates of reduction as high as 48% among men 15-19 years14.  
Despite the reduction in HPV disease burdens realized in high income countries, cervical cancer 
remains a global public health priority. This is due to unacceptably high current and forecasted 
cervical cancer incidence in lesser resourced nations, particularly the world’s poorest17. Higher 
cervical cancers in poorer countries results from inadequate cervical cancer prevention programs 
for screening and effective treatment of cervical cancer precursor lesions18,19. The proven 
effectiveness of HPV vaccination in reducing HPV infections led to its inclusion as an essential 
component in the World Health Organization’s (WHO) Global Strategy Towards the Elimination 
of Cervical Cancer as a Public Health Problem. This Global Strategy outlines 2030 country-level 
targets for primary, secondary and tertiary prevention through vaccination, screening and 
treatment, respectively. These targets are: 90% of girls being fully vaccinated against HPV by age 
15; 70% of women receiving high-precision HPV screening at ages 35 and 45 years; and 90% of 
women identified with cervical cancer receiving treatment and care. The achievement of these 
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targets by each country is proposed to enable a reduction in cervical cancer incidence to less than 
4 per 100,000 women-years within the twenty-first century17. 
There are, however, challenges to achieving the primary prevention target using HPVVs with 
multi-dose schedules that require two or sometimes three visits within one year. Such schedules 
can be challenging for vaccine delivery mechanisms. For example, school-based delivery of two 
or three doses within six months, as done in provinces across Canada20 and in many high-income 
countries, require health-care professionals to make multiple visits to schools within a single 
school year. Another factor that operates at the global macro level, is socioeconomic disparity that 
contributes to inequities in access. This is apparent as HPV vaccination has been implemented in 
84% of high-income countries but only 31% and 12% of middle and low-income countries, 
respectively21. Further, projections show that current production capacities of HPVVs are well 
below the volumes required to achieve vaccination coverage required by the WHO’s Global 
Strategy21,22. Within countries, expanding vaccination coverage is also impeded by additional 
contextual social, personal and health system factors23–26. Considering the myriad of interacting 
factors, the Global Strategy promoted by the WHO has also called for research to simplify HPVV 
schedules and “achieve the same population impact at a lower cost”21. One way to achieve this 
simplification is to increase the interval between doses. For immunocompetent children 9-14 years, 
the preferred recommended schedule for administering the HPVV is two doses, spaced at an 
interval of 6 months. Although a six-month interval is favoured, the WHO indicates that with the 
absence of evidence of the maximum interval between doses where the vaccine remains effective, 
intervals of 12-15 months are also acceptable6. If these two doses could be administered later, even 
longer than 12-15 months apart, then vaccine doses needed per year could be substantially reduced, 
at least until supply capacity can meet demand. Further logistical arrangements to deliver the two 
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doses within 6-15 months could be reduced. Longer intervals would also more readily facilitate 
co-administration of HPVV with other vaccines required by the primary target group (girls 9-14 
years). A recent systematic review using relevant studies available up to September 2018, Bergman 
et al found that longer intervals for two-dose schedules provided stronger antibody response than 
shorter intervals. This was based on studies comparing an extension of the two-dose interval from 
2 to 6 months, and also from 6 to 12 months27. Improved antibody response of a six-months interval 
relative to a two-months interval between doses for two-dose schedules was already well 
established in females 9-14 years. It is unclear however, if the trend of increasing antibody 
response with interval length extends to intervals beyond twelve months. In consideration of the 
HPVV shortage the WHO Strategic Advisory Group of Experts (SAGE) on Immunization 
suggested that spacing two doses at intervals of 3-5 years could be considered, but would constitute 
“off-label” use of the vaccines28. A synthesis of evidence from the current body of knowledge, that 
includes two-dose intervals beyond 12 months could provide timely insights on the potential of 
such extended-dose schedules to effective. Further, Bergman et al 202014 did not examine the 
effect of extended intervals on cell-based immune responses or HPV-related diseases. This paper 
therefore extends upon the work of Bergman et al 2020, by comparing the effect of using dosing 
intervals beyond seven months on humoral and cellular immunogenicity, as well as effectiveness 
of HPVVs. This will provide additional insights relevant to optimizing HPVV schedules.  
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Purpose of the Paper 
Vaccination is a highly effective strategy for primary prevention of HPV infection, cervical cancer 
precursors and other HPV-related diseases. Despite the demonstrated effectiveness of HPVVs, 
their population-level impact has not been maximized29, largely due to limited access in lower 
income countries resulting from financial constraints, as well as suboptimal vaccine coverage and 
compliance with multi-dose vaccine schedules globally30,31. Optimizing vaccination schedules is 
necessary for the success of vaccination programs and the elimination of cervical cancer. The 
number of vaccine doses and their spacing are critical features of the vaccination schedule. 
Simplifying vaccine schedules by reducing the number of doses or allowing for more flexible 
spacing of follow-up doses could improve population vaccine coverage, completion of vaccine 
series and may improve the cost-effectiveness of vaccination programs32,33. An increase in the 
spacing of the two doses could be more convenient for administration of the vaccine to patients, 
and probably allow more efficient integration of the HPVVs with other routinely-administered 
vaccines. Recent shortfalls in the supply of all three HPVVs34 threaten to constrain the WHO’s 
Global Strategy Towards the Elimination of Cervical Cancer as a Public Health Problem, which 
aims to expand vaccine coverage and protection against HPV. Allowing extended intervals for 
HPV vaccination would ease administration for public health. In addition, with the current global 
shortage in HPVV supplies, longer intervals between doses could reduce the shortfall between 
supply and demand by delaying the second dose until supply increases. Evidence of the 
immunogenicity and effectiveness of HPVVs when the two doses are spaced at longer time 
intervals could therefore inform possible flexibility regarding existing HPVV schedules.  
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Review Question 
Do intervals longer than 6 months affect the immunogenicity, efficacy/effectiveness of HPVVs 
administered in a two-dose schedule to children aged 9-14 years and young adults 15-26 years 
compared to a six month interval? 
Objectives 
1) To determine whether HPVV schedules of 0, 6 months (+/- 1 month) and 0, 7+ months are 
non-inferior in the level of antibody response and seroconversion rates for children aged 
9-14 years and young adults 15-26 years. 
 
2) To determine whether HPVV schedules of 0, 6 months (+/- 1 month) and 0, 7+ months are 
non-inferior in cellular immune response for children aged 9-14 years and young adults 
15-26 years. 
 
3) To determine whether HPVV schedules of 0, 6 months (+/- 1 month) and 0, 7+ months are 
non-inferior in their efficacy in protecting against HPV infections and HPV-related 
diseases for children aged 9-14 years and young adults 15-26 years. 
  
4) To determine whether HPVV schedules of 0, 6 months (+/- 1 month) and 0, 7+ months are 
non-inferior in their effectiveness in protecting against HPV infections and HPV-related 
diseases for children aged 9-14 years and young adults 15-26 years. 
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Critical Review of Relevant Literature 
HPV Vaccines and Basis of Protection (Immune Response) 
HPVVs are recombinant subunit vaccines containing the major capsid L1 protein of vaccine 
strains. Three HPVVs are currently licensed for use. The bivalent vaccine was licensed in 2007 
and targets HPV types 16 and 18. The quadrivalent vaccine was licensed a year earlier and targets 
HPV types 6 and 11 in addition to HPV types 16 and 18. The nonavalent vaccine was licensed in 
2014 and protects against HPV types 31, 33, 45, 52 and 58, in addition to the four types that the 
quadrivalent vaccine protects against6.  
HPVVs are prophylactic and provide greatest protection when individuals are vaccinated prior to 
HPV exposure, usually, before sexual debut35,36. HPVVs trigger the adaptive immune system to 
produce elevated levels of antibodies, B-cells and T-cells that target HPV antigens for 
neutralization and destruction37–40. A study of cervical secretion samples after intramuscular 
vaccination showed that there is exudation of serum antibodies to the mucosa to bolster protection 
against natural HPV infection41,42. This protection is durable over the long term due to long-lasting 
antibody producing B-cells and memory B-cells43–45. It is proposed that long-lasting plasma B-
cells contribute to the sustained persistence of antibody protection43. Memory B-cells direct the 
proliferation and rapid production of antibody producing B-cells if HPV challenge occurs 
subsequently, this is known as the anamnestic response43–45. Helper T-cells are proposed to play 
an accessory role in supporting the development and maintenance of an effective antibody 
response41,46. Since HPVVs contain a component of the viral capsid, they stimulate antibodies that 
neutralize the HPV particle to prevent establishment of infection. The vigorous antibody response 
induced by the HPVVs is therefore highly protective when vaccines are administered prior to 
infection47,48.  The minimal anti-HPV antibody threshold required for effective protection against 
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HPV infections and HPV associated diseases is unknown36,42,49. During the peak antibody response 
to HPVV,  neutralizing antibody levels are as much as 100 times above that of natural HPV 
infection50,51. Natural HPV infection, even with its much-reduced antibody elicitation, also 
generates protective antibody levels in a subset of infected individuals52, albeit insufficient to fully 
protect against subsequent reinfection53. It is known however, that antibody levels generated by 
HPVVs in young women, 15-26 years old, on a three-dose schedule shows efficacy in preventing 
HPV infection and associated genital diseases including CIN2+ up to five years post-
vaccination47,48. Consequently, it was recommended that evaluation of different schedules of 
HPVVs in girls 9-14 years, is by assessing non-inferiority of their antibody response to the 
antibody response among women 15-26 years, assuming that with comparable immunogenicity 
also efficacy would be comparable. In 15-26 year old women, efficacy against clinical outcomes 
after three-dose schedule is established39,51. This principle is called immunobridging.   
Evolution of HPV Vaccine Schedules 
All three HPVVs were originally approved for administration on a three-dose schedule54. The first 
two prime doses were administered 1-2 months apart, followed by a boosting dose after a longer 
interval. This schedule was guided by the Hepatitis B vaccine which is also a recombinant 
vaccine44. Such a schedule was thought to be necessary to generate long-lasting antibody and 
cellular memory response to recombinant subunit vaccines51. Multiple studies have since showed 
that alternate schedules where the dose intervals were extended or the number of doses reduced 
are as immunogenic as three-doses, and therefore comparable protection is assumed44,46,51,55,56.  
Using the immunobridging comparison, it was found that two doses provide acceptable protection 
for females under 15 years of age35,57,58. With these insights, the WHO revised the  recommended 
HPV immunization schedule for immunocompetent adolescents under 15 years to two doses to be 
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administered at an interval of 6 months between doses (0, 6 months) for the quadrivalent vaccine 
and an interval of 5-13 months between doses (0, 5-13 months) for the bivalent and nonavalent 
vaccines1,6,59. The three-dose schedule for individuals 15 years and over were maintained1,6,59, but 
there have been recent suggestions that the two-dose recommendation should be extended to 
individuals up to age 1860,61. 
Studies utilising data from delayed or incomplete HPVV series revealed preliminary insights into 
the effectiveness of alternate schedules. LaMontagne et al 62 proposed that the vaccine schedule 
impacts the timing of the peak antibody response. In their study of alternate three-dose schedules, 
LaMontagne et al found that a schedule administered at 0, 12, 24 months was inferior with regard 
to antibody levels to the standard schedule administered at 0, 2, 6 months at 1 month post-last-
dose, but non-inferior at 32 months post-last-dose62. Although the 0, 12, 24 months schedule 
produced antibody levels at 1 month post-last-dose that were lower compared to the standard 
schedule, it is not known whether this translates to lower protection during this period, since the 
minimal immune correlates of protection against HPV infection have not been established51,63. 
Another alternate schedule that shows promise is administering two doses with intervals beyond 
one year64,65. Together, the insights into the immunogenicity of alternate schedules of HPVVs 
suggest that more flexibility regarding the recommended intervals of HPV vaccination schedule 
may be possible. With a two-dose schedule of 0, 6 months being the standard commonly applied 
for children 9-14 years, assessment of the effect of extending the interval beyond 6 months could 
delineate an ideal maximum time interval for administering the second dose. Insights of potentially 
efficacious extended intervals are especially valuable in guiding decision making to maximise 
public health benefits.  
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Vaccine Schedule as a Moderator of Immune Response 
The timing of the administration of HPVV doses in relation to each other as well as the age 
administered can moderate the levels of anti-HPV antibodies produced post-vaccination. A study 
of three-dose schedules with different intervals found that delayed administration of the second 
dose resulted in increased antibody titers relative to when the second dose was administered on-
time, according to the 0, 2, 6 month schedule66. This study also found that antibody levels produced 
from delayed administration of the third dose were non-inferior to that of on-time administration 
of the third dose. Also, antibody levels generated by a 0, 1 month or 0, 2 month schedule of the 
bivalent HPVV were inferior to that generated when the vaccine was administered on a 0, 6 month, 
two-dose schedule66,67. Timing also impacts the effectiveness of the quadrivalent HPVV against 
condyloma. Compared to the standard three-dose schedule (0, 2 6 months), two doses given 4-7 
months apart had similar effectiveness against condyloma, whilst two doses given 0-3 months 
apart had reduced effectiveness68. These indications that the timing of HPVV doses impacts both 
levels of HPV antibodies and protection against condyloma, warrants exploration of optimal 
timing for the second dose of the HPVV in a two-dose schedule. Understanding optimal timing of 
the second dose could guide refinements of HPV vaccination programs globally to improve 
vaccine delivery and ultimately population protection.  
Systematic Reviews and Meta-analyses 
The recognition of systematic reviews as a formal type of research with recognizable value for 
evidence synthesis occurred in the 1970s69. Standardized methodologies and tools have been 
developed for executing systematic reviews70,71. These standards aim to ensure that the products 
of the substantial efforts required to execute a systematic review generate high quality, organized, 
appraised and integrated evidence of minimal bias. Such evidence is significant for decision 
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making in health and social contexts to enhance accountability72. Systematic reviews may include 
a meta-analysis as a quantitative synthesis of the accumulated evidence on the topic. The term 
meta-analysis was coined in 1976 by Gene Glass and methods for appropriate integration and 
statistical analyses of data from multiple studies have also subsequently been developed73. This 
analysis will apply relevant standards, methodologies and tools, developed for systematic reviews 
and meta-analyses, to explore the defined research question. 
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Methods 
A protocol was developed for the execution of this systematic review and registered with the 
International Prospective Register of Systematic Review (PROSPERO), under protocol number: 
CRD42019141959. Reporting of the review was done according to with the preferred reporting 
items for systematic reviews and meta-analyses (PRISMA) guidelines.  
 
Literature search and study selection 
Briefly, a population, intervention, comparator and outcome (PICO) search strategy was developed 
and used to conduct a systematic search for relevant studies in peer-reviewed and grey-literature 
databases. The databases: MEDLINE (Ovid), EMBASE (Ovid), Cochrane Central Register of 
Clinical Trials, PUBMED and CINAHL were searched using this PICO search strategy (Appendix 
1), which was adapted to each database based on their syntax and thesaurus. The search term “HPV 
Vaccine” was used to search ClinicalTrials.gov, GSK study register, MERCK clinical trials, 
International Clinical Trials Registry Platform, EU Clinical Trials Register and Drugs@FDA for 
grey literature. Two review team members, ACF and RD, screened references for suitability based 
on pre-defined inclusion criteria. Inclusion criteria were:  
1. study participants received first HPVV dose between age 9-26 years inclusive,  
2. administration of any combination of bivalent, quadrivalent or nonavalent HPVVs in a 
two-dose schedule to females and/or males and  
3. presentation of data on immunogenicity, effectiveness or efficacy of two doses of HPVV 
administered 0,6 months (+/- 1 month) as well as two doses administered 0,7+ months.  
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Studies were excluded if: 
1. any other agent was administered simultaneously with HPVV for treatment of or protection 
against HPV related outcomes,  
2. only populations with specific diseases were included,  
3. the second dose of HPVV was administered earlier than five months after the first dose,  
4. the vaccine formulation administered is different from the licensed vaccine formulation, or  
5. the study is reported in a language other than English.  
 
Data Extraction and Analyses 
Data were independently extracted from included studies by ACF and RD onto prepared data 
extraction worksheets and both sets of extracted data checked for agreement and accuracy by ACF. 
Bias in each study was assessed using the Cochrane Risk of Bias v2 for clinical studies74 and the 
Cochrane Risk of Bias in Non-Randomised Studies of Intervention (ROBINS-I)75 tool for 
observational studies. The quality of the evidence available to assess each study objective was then 
assessed using the Grades of Recommendation, Assessment, Development and 
Evaluation (GRADE) approach76. 
Outcome measures reported for immunogenicity and effectiveness indicators were used to derive 
a relative measure for comparing schedules of 0, 7+ months (0, 7+m) to the reference schedule of 
0, 6 months (0,6m). To validly compare effects across studies, within-study relative measures for 
the effect of 0,7+m versus 0,6m intervals on immunogenicity outcomes were first generated to 
obtain an effect measure that controls for inter-study methodological variations such as antibody 
assays77. Using Revman 5.2, relative measures were then pooled across studies with identical study 
design and low to moderate heterogeneity, I2 <50%, to provide a pooled estimate of effect. Non-
Page 19 of 64 
 
inferiority (NI) was then assessed using specified NI margins for the pooled estimates (Table 1). 
These NI margins were adopted from previous non-inferiority studies related to HPVVs and their 
use will facilitate comparison of our findings to previous studies 78,79. Where NI was demonstrated, 
superiority was assessed, as pre-specified in the protocol for this review. Superiority is 
demonstrated when the lower limit of the 95% CI of the estimate exceeds 1 for ratios and 0 for 
differences in proportions or rates.  
 
Table 1: Non-Inferiority Margins Used in Comparing 0, 7+m vs 0,6m Schedules 
 
Outcome Measures Non-Inferiority Margins for  
0,7+m vs 0,6m 
Lower limit of 95% 
confidence interval is: 
Immunogenicity   
  Antibody Levels GMC/T > 0.5 for ratio 
  Cell based Immunity HPV type specific B or T-cells 
per million B or T-cells 
> 0.5 for ratio 
  Seroconversion  Proportion > -10% for difference 
Effectiveness   
  HPV Infection Proportion  
Rate 
 
> -10% for difference  
 0 for rate difference  
  Rates of Any  
  HPV Related Disease 
Rate  0 for rate difference  
GMC/T= Geometric mean concentration or titer. 
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Results 
Description of Included Studies 
Of the 1276 records screened for eligibility, 11 were selected for inclusion in this systematic 
review (Figure 1) and these represented four unique studies. Each is described below and a 
summary of included publications provided in Table 2. 
Figure1: PRISMA Flow chart describing the study selection process.   
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2v @ 0,6m 






● ● ● ● ● ◌ ● ● ● ● ● ◌ ● ● ● ● ● ◌ ◌ ◌ 
Huang etal 
2017 
● ● ● ● ● ◌ ● ● ● ● ● ◌ ● ● ● ● ● ◌ ◌ ◌ 
Puthanakit 
et al 2016 
● ● ◌ ◌ ◌ ◌ ● ● ◌ ◌ ◌ ◌ ● ● ◌ ◌ ◌ ◌ ◌ ◌ 
                          
2 NCT01984697 F, 9-14 
M, 9-14 
FM, 9-14 
9v @ 0,6m 
9v @ 0,6m 







● ● ◌ ● ● ◌ ● ● ◌ ● ● ◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ 
Iversen etal 
2016 
● ● ◌ ● ● ◌ ● ● ◌ ● ● ◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ 
Joohee etal 
2016 
● ● ◌ ◌ ◌ ◌ ● ● ◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ 
Yan etal 
2016 
● ● ◌ ◌ ◌ ◌ ● ● ◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ 
                          





9v @ 0,6m 
4v/9v @ 36-96m 
173 




● ◌ ◌ ◌ ◌ ● ● ◌ ◌ ◌ ◌ ● ◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ 
                          





4v @ 4-7m 
4v @ 8+m 
 
 
4v @ 4-7m 











◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ ◌ ● ◌ 
●= available data, ◌= no data, 2v= bivalent HPV vaccine, F= female, M= make, FM= female and male, 4v= quadrivalent HPV vaccine, 9v= nonavalent HPV vaccine, 4v/9v= 
mixed regimen of 4v then 9v HPV vaccine, GMC/T= geometric mean concentration/titres from enzyme linked immunosorbent assay, competitive luminex immunoassay or 
pseudoviron based neutralization assay, AGW= ano-genital warts, *= source from which data were extracted when multiple publications available 
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GSK_NCT01381575 (Bivalent study) 
Study NCT0131575 is a GlaxoSmithKline (GSK) sponsored study, conducted from June 29, 
2011 to June 28, 2014. It is a RCT that evaluated the immunogenicity and safety of GSK’s 
HPV16/18 vaccine (Cervarix®) when administered according to alternative 2-dose schedules of 
0,6 months and 0,12 months in females 9-14 years compared to the standard 3-dose schedule 
(0,1,6 months) in 15-25 year old females. Primary study outcomes measured were number of 
anti-HPV16/18 seroconverted participants at one month after the last vaccine dose, as well as 
anti-HPV 16 and anti-HPV-18 antibody concentrations, measured by Enzyme Linked 
Immunosorbent Assay (ELISA) at one month after the last vaccine dose. Secondary outcomes 
related to immunogenicity were:  
1. seroconversion for anti-HPV16/18 after dose 1 at day 0, then at months 7, 12, 18, 24 and 
36 for participants receiving vaccine at 0,6 months and 0,1,6 months, and at day 0, 
months 13, 18, 24 and 36 for participants receiving vaccine at 0,12 months; 
2. anti-HPV16/18 measured by ELISA after dose 1 at day 0, then at months 7, 12, 18, 24 
and 36 for participants receiving vaccine at 0,6 months and 0,1,6 months, but at day 0, 
months 13, 18, 24 and 36, for participants receiving vaccine 0,12 months; 
3. anti-HPV16/18 neutralising antibody measured by PBNA for a subset of participants 
after dose 1 at day 0, then at months 7, 12, 18, 24 and 36 for participants receiving 
vaccine 0,6 months and 0,1,6 months and at day 0, then months 13, 18, 24 and 36 for 
participants receiving vaccine at 0,12 months; 
4. Anti-HPV 16/18 specific T-cell after dose 1 at day 0, then at months 7, 12, 24 and 36 for 
participants receiving vaccine at 0,6 months and 0,1,6 months and at day 0, then months 
13, 18 and 36 for participants receiving vaccine at 0,12 months; 
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5. Anti-HPV16/18 specific memory B-cells after dose 1 at day 0, then months 7, 12, 24 and 
36 for participants receiving vaccine at 0,6 months and 0,1,6 months and at day 0, then 
months 13, 18 and 36 for participants receiving vaccine at 0,12 months. 
Data from this study was reported by four publications identified by our search strategy (Table 
2). This study will be subsequently referred to as the bivalent study80.  
 
Merck_NCT01984697 (Nonavalent study) 
This study was sponsored by Merck Sharp & Dohme Corporation. It is a RCT that investigated 
the safety and immunogenicity of nonavalent HPVV when administered in alternate two-dose 
schedules of 0,6 months and 0,12 months in boys and girls 9-14 years, compared to women 16 to 
26 years who received standard three-dose regimen at 0, 2, 6 months. The primary study 
outcomes were antibodies to vaccine HPV types (HPV6, 11, 16, 18, 31, 33, 45, 52 and 58) at 1 
month after the last dose of planned regimen, as measured by competitive Luminex Imunoassay 
(cLIA). Secondary outcomes were: 
1. seroconversion to HPVV types at 1 month after last dose of the planned regimen;  
2. persistence of vaccine type antibodies, measured by cLIA at months 24 and 36 after the 
first dose; 
3. persistence of vaccine type antibodies, as measured by percentage seroconverted 
participants to vaccine type HPV at months 24 and 36 after first dose.  
Data from this study was reported by five of the publications identified by our search strategy 
(Table 2). This study will be subsequently referred to as the nonavalent study81.  
 
 




Gilca et al 2019 
This non-randomised study was a post hoc analysis comparing anti-HPV6, 11, 16 and 18 
antibody response measured by ELISA, of 173 males and females aged 9-10 years who received 
two-doses of nonavalent vaccine at 0, 6 months (6m), to 31 girls aged 9-14 years who received 
quadrivalent vaccine as a first dose and nonavalent vaccine as a second dose 3-8 years later. The 
0, 6m participants were the comparator group for a separate RCT (NCT02567955), and was 
adopted as the comparator group for this post hoc analysis. Participants in the intervention group 
that received vaccine at 0, 36-96 months (36-96m) were identified in a school-based vaccination 
database as non-compliant cases who completed only one dose of the recommended two-dose 
vaccine schedule. This study will be subsequently referred to as Gilca et al64.  
 
Lamb et al 2017 
This is a cohort study, that assessed the incidence of condyloma in Swedish women initiating 
HPVV between 2006 and 2012, and who received two doses of the quadrivalent vaccine at 
varying intervals between doses, including intervals of 4-7 months (4-7m) and 8 or more (8+m). 
National registries were linked to provide the study exposure and associated outcome data. This 
study will be subsequently referred to as Lamb et al68.  
 
Risk of Bias Analysis 
The two randomised studies had an overall low risk of bias (Figure 2), when judged using the 
RoB2 tool. The only area that not ideal was the lack of blinding in regard to participants’ 
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assigned study group, ie. receiving vaccine at 0, 12 months (12m) versus 0, 6 months (6m), in 
both studies. The effect of lack of blinding in these studies where biomarkers such as antibody 
levels and cell frequencies are the outcomes assessed, is anticipated to be low.  
The observational studies by Gilca et al and Lamb et al were assessed using the ROBINS-I tool. 
Gilca et al 2019 was assessed to have an overall moderate risk of bias (Figure 3). Confounding 
by indication and volunteer bias could potentially be operating in this study. Confounding by 
indication could arise since participants in the 36m group were all non-compliant vaccinees. 
Social deprivation was associated with lower vaccination coverage in Quebec82 (the province 
where this study was done), and in Ontario lower income was associated with incomplete 
vaccine series83. The antibody response is generally robust to sociodemographic factors such as 
race and region of residence84, however we cannot completely exclude the chance that 
sociodemographic factors associated with vaccine non-compliance could distort the true effect of 
a 36-96m interval GMT. Additionally, higher vaccine-type antibody titres have been observed or 
girls who were seropositive for HPV prior to HPVV than for girls seronegative at baseline48,84. 
The 36-96m of vaccine non-compliance provides substantially greater opportunity for higher 
HPV exposure, which could potentially inflate the peak GMT observed after the second vaccine 
dose, again distorting the true effect of the 36-96m interval. No information on the sexual risks 
of the comparator and intervention groups were reported. There is also a potential for volunteer 
bias in this study since only non-compliant vaccinees who consented to receiving the second 
dose could be included. The authors however, did not report the proportion of the eligible 
population that consented or how representative they are. This publication completed the peer-
review process without the aforementioned information being included. It may be an indication 
that the authors and reviewers did not consider that information to be highly influential on the 
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outcome of antibody concentration. Although the missing information would have supported 
firm establishment of the quality of the evidence from this study, the extent to which they would 
bias a robust, objective biomarker like antibody levels is not definitively clear. Consequently a 
more severe risk of bias rating than moderate was not assigned.  
Lamb et al was assessed to have moderate risk of bias due to residual confounding68. The results 
of the risk of bias for the randomised and non-randomised studies are presented in Figures 1-2. 
Detailed risk of bias assessments are provided in Appendix 2. 
 
Figure 2: Traffic light plot summarizing the risk of bias assessment of the two randomised 
controlled trials included in this study.  
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Figure 3: Traffic light plot of risk of bias assessment of non-randomised studies included in this 
systematic review.  
 




Synthesis of Outcomes 
Immunogenicity 
Three studies examined the effect of two-dose schedules with time intervals of 6m compared to 
7+m between two doses, on HPVV immunogenicity. Two of these studies, the bivalent and the 
nonavalent studies examined 0, 12m and 0, 6m two-dose schedules. The third study, Gilca et al, 
compared a 0, 6m dose interval to a 36-96m dose interval. The effects of the 7+m interval is 
therefore reported in terms of 0, 12m and 0, 36-96m. Immunogenicity was reported in terms of 
seroconversion rates, humoral antibody response, and cellular immune responses. 
 




Seroconversion and Seropositivity  
One month after administration of the last dose of HPVV, seroconversion to vaccine-type HPV 
for the 0, 12m schedule was non-inferior to that of the 0, 6m schedule when two doses of the 
bivalent or two doses of the nonavalent vaccines were administered (Figure 4). The bivalent 
vaccine also showed non-inferior seropositivity to vaccine-type HPV for the 0, 12m schedule 
compared to the 0, 6m schedule, and this persisted up to 1 year post-last-dose, which was the 
maximum duration of follow-up for which data was reported (Figure 5). No data were available 
to assess the immunogenicity of 0, 12m versus 0, 6m interval for two doses of the nonavalent 
vaccine beyond 1m post-last-dose. Contrasting to a regimen of two doses of bivalent or 
nonavalent vaccines, non-inferiority in vaccine-type HPV seroconversion was not demonstrated 
for a mixed quadrivalent-nonavalent regimen, when the two doses were administered at a 0, 36-
96m interval versus a 0,6m interval (Figure 4). The very wide confidence intervals for 
seroconversion difference based on data reported for this mixed schedule included the non-
inferiority margin of -10% difference in seroconversion for all four HPV types (6/11/16/18) and 
above 0.0%, even though the point estimates were 0.0% (95% CI: -11.07%, 2.18%). The point 
estimate and confidence intervals suggest that seroconversion could be worse, better or no 
different, and so this study is inconclusive in regards to the relative effects of 0,36-96m versus 
0,6m schedules on the seroconversion rates for HPVVs. Further, no data is currently available 
beyond 1m post-last-dose, as such the seroconversion difference between schedules of 0,36-96m 
and 0,6m for this regimen could not be assessed over time. There was also no indication of 
heterogeneity in seroconversion across the studies (I2=0). 






Figure 4: Difference in seroconversion to vaccine type HPV strains between two-dose schedules 
administered at 0,7+m versus 0,6m, at 1m after last HPV vaccine dose. 
2v=bivalent vaccine, 4v=quadrivalent vaccine, 9v=nonavalent vaccine, squares = mixed 
schedule of quadrivalent and nonavalent HPV vaccine reported by Gilca et al (2019), triangles = 
two doses of nonavalent vaccine reported by the nonvalent study81, circles= 2 doses of bivalent 
vaccine reported by the bivalent study80. The line at -10% is the pre-specified non inferiority 
margin for the ratio of the 0, 7+m interval group versus 0, 6m interval group. The line at 0 
represent no difference. 95% Confidence Interval were calculated using Wilsons exact approach 
without continuity correction. 
   
 





Figure 5: Trend in seropositivity difference of 12m versus 6m intervals between two doses of 
bivalent HPV vaccine, from 1 month post last dose to 12 months post last dose. 
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Antibody levels 
At one month post-last-dose of HPVV, a 12m interval between two doses of bivalent or 
nonavalent vaccine was superior to a 6m interval in antibody response to almost all vaccine-type 
HPV. This superiority was demonstrated since the lower limit of the confidence intervals of 12m 
to 6m geometric mean concentration or titer (GMC/T) ratios exceeded 1 for all vaccine-types, 
except for HPV18 when the bivalent vaccine was administered (GMC/T ratio 1.11,  95%CI: 1.00 
to 1.23, Figure 6). GMC/T ratios for HPV16 and 18 for the bivalent and nonavalent vaccines 
showed substantial heterogeneity for the ratio of the peak antibody response at 1m post-last-dose 
(I2 = 76%), precluding pooling of these data. The 12m interval provided antibody responses 
superior to the 6m interval for HPV16 and 18 at 6-12m post-last-dose for the bivalent vaccine 
(Figure 7). A two dose interval of 36-96m between doses was non-inferior to a 6m interval in 
antibody response to HPV6, 16 and 18, but not HPV11 (GMC/T ratio 0.63, 95%CI: 0.41 to 0.97, 
Figure 6). Estimates of the GMC/T ratio for 0, 36-96m vs 0, 6m based on the mixed vaccine 
schedule reported by Gilca et al 2019 were the lowest among the three studies. The confidence 
intervals were also the widest of the three studies. This imprecision is not surprising considering 















Figure 6: Vaccine type HPV antibody ratios for two dose schedules administered at intervals of 
0, 7+m versus 0, 6m at 1 month post-last HPV vaccine dose. 
 
2v=bivalent vaccine, 4v=quadrivalent vaccine, 9v=nonavalent vaccine, squares = mixed 
schedule of quadrivalent and nonavalent HPV vaccine reported by Gilca et al (2019), triangles = 
two doses of nonavalent vaccine reported by the nonvalent study81, circles= 2 doses of bivalent 
vaccine reported by the bivalent study80. The line at 0.5 is the pre-specified non inferiority 
margin for the ratio of the 0, 7+m interval group versus 0, 6m interval group. The line at 1 
represent no difference.  




Figure 7: Variation in the antiHPV16 and antiHPV18 antibody response from 1-12 months post-
last-dose of bivalent vaccine reported in the bivalent study80. 
 
Grey line indicates no difference and the black line indicates the 0.5 non-inferiority margin. 
 
 
Cellular Response  
Memory B-cell and T-cell immune response were measured in a subset of participants in the 
bivalent study. No CD8+ T cell response to HPV16/18 was detectable for any of the evaluated 
schedules. The memory B-cell and CD4+ T-cell response were of similar magnitude for the 0, 
12m and 0, 6m schedules, at 36m post-dose-one. The study authors noted however, that the 
number of participants observed would not have provided sufficient statistical power to detect 
differences between the groups.   




Data on the effectiveness of extending the interval between two doses of HPVV in the two-dose 
schedule is limited. A total of eight HPV-related diseases were specified as outcomes of interest 
to assess the effect of the length of the dose interval in two-dose schedules on HPVV 
effectiveness. Data at this time was only available for AGWs as an outcome. This data was 
provided by one study, Lamb et al, that investigated the effect of time intervals of 4-7m and 8+m 
on AGW incidence. Increasing the interval between two doses, from 4-7m to 8+m was 
associated with an non-significant increase in AGW incidence rate, for females younger than 17 
years (IRD 256.21, 95%CI -12.11, 524.53 per 100,000 person-years) as well as those aged 17-19 
years (IRD 448.62, 95%CI -49.41, 946.64 per 100,000 person-years). These are inconclusive 
findings since they include both the non-inferiority margin as well as the margin of no 
difference.  
 
GRADE Assessment  
Assessment of inconsistency, indirectness and imprecision were based on the guidelines 
provided by Meader et al (2014) to improve consistency and reproducibility of GRADE 
assessments85. Effect estimates based on the bivalent and nonavalent vaccines were assessed to 
have high certainty due to them being RCTs with low risk of bias and sample sizes of over 100 
participants per study group. Effect estimates based on Gilca et al and Lamb et al were assessed 
to be of low certainty due to their moderate risk of bias and wide confidence intervals. These are 
effects of their observational study design and in the case of Gilca et al, the small size of the 0, 
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36-96m group (31 participants) contributed greatly to the imprecision. The  complete GRADE 
assessment is provided in Appendix 3.





In this systematic review we investigated the effect of dose intervals of 0, 7+m versus 0, 6m on 
the immunogenicity and effectiveness of two doses of HPVVs. We found the effect to be 
dependent on: HPV type, HPVV and the length of the two-dose interval beyond 6 months. An 
interval of 12m generally improved the antibody response when compared to a 6m interval 
between two HPVV doses. This concurs with the report by Bergman et al 2020, that increasing 
the two dose interval from 0, 6m to 0, 12m increases immunogenicity 27. The length of the 
interval between the prime and boost vaccine doses mediates the extent to which stimulation and 
maturation of antibody producing B-cells is achieved before boosting44,86. Compared to a 6m 
interval, a 12m interval would allow the processes involved in stimulation and maturation of 
antibody-producing B-cells to reach further completion before boosting. This could be a reason 
for the increased antibody response generally observed for 12m versus 6m intervals.  
While a 12m two-dose interval was generally superior in antibody response to a 6m interval, a 
36-96m two-dose interval was non-inferior for HPV6, 16, and 18, but not so for HPV11. It is 
notable that evidence for the 36-96m interval was drawn from a non-randomised study with at 
least moderate potential for confounding, a low sample size (31 individuals for the 0, 36-96m 
and 173 individuals for the 0, 6m) that gave inconclusive results for seroconversion difference 
(0.00%, 95% CI: -11.07%, 2.18%) and wide confidence intervals around the antibody response 
to the vaccine-type HPVs. Nevertheless, the non-inferiority of the extended 36-96m interval to a 
6m interval for hrHPV types is encouraging in its potential to be used for vaccination programs 
against cervical cancer. The clinical significance of the HPV11 antibody response failing to 
Page 37 of 64 
 
achieve non-inferiority when two doses are administered on a 36-96m schedule versus 0,6m 
schedule is unclear. As previously mentioned, a minimum antibody level required for protection 
against HPV infection has not been established63, as well, the presence of memory B-cells may 
be enough to trigger a protective anamnestic response during natural HPV infection, even if 
plasma antibody levels become low or even undetectable post-vaccination 45,87. Further studies 
are required to confirm the performance of the 36-96m interval.  
 
Efficacy and Effectiveness 
AGW was the only clinical outcome for which data was available to assess the impact of 
extending the two-dose intervals on HPVV efficacy or effectiveness. Non-inferiority analysis 
based on these data was however inconclusive with incidence rate difference of 256.21, 95%CI -
12.11, 524.53 per 100,000 person-years.  
There is a clear need for high quality empirical evidence to assess the impact of extending 
intervals for two-dose schedules beyond 6 and 12 months, on the performance of HPVV in 
relation to accepted primary end-points51 for HPV diseases. Assessing efficacy or effectiveness 
of the HPV vaccine among 9-14 year olds using cervical samples is constrained by ethical 
considerations51, since most in this age group have not initiated sexual contact. Perhaps AGW 
incidence could be explored as a proxy for efficacy and effectiveness among this age group. 
Lamb et al demonstrated this by investigating AGW incidence among 10-16 year olds using 
registries. More precise estimates should be pursued. 
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Strengths and Limitations 
This systematic review was executed according to a previously published protocol and focuses 
on the effect of extending dose intervals beyond six months on the two-dose HPV vaccine 
schedule. It was comprehensive in the search for eligible studies based on the range of databases 
queried. In regards to its focus, this review is more comprehensive than Bergman et al (2020) 
since it incorporates all available randomised and non-randomised studies comparing the effect 
of intervals of 6m or longer on HPVV immunogenicity and clinical outcomes. Including insights 
from additional sources is especially important given the limited reported data examining the 
effect of increased intervals between two HPVV doses. It is also a recommended practice88,89 and 
for this review it provided more nuanced insights into the effect of dose intervals greater than 
6m. A poignant concern with including non-randomised studies in systematic reviews, is their 
potential for increased risk of bias. With this in mind, we qualitatively incorporated insights from 
non-randomised and randomised studies, rather than pooling data across study designs71,90. It is 
notable that two studies included in this review, the nonavalent study by Merck and Gilca et al, 
included males 9-14 years as study participants. This is acceptable, as HPV vaccine antibody 
response has not been shown to be sex-dependent36,57,91. Comparison of vaccine schedules have 
been done using time post-dose-one and time post-last-dose. This study used time post-last-dose 
only, as it reveals the true time-matched relative effects of schedules with different dose 
intervals. Rather than comparing absolute antibody measures, we generated relative measures 
between the 0,7+m and 6m time intervals and compared these relative measures. In so doing we 
would have minimised the influence of between-study methodological variations on the 
inferences generated. A less than ideal step of our methodology, was the performance of the 
ROBINS-I assessment by a single team member (MPH candidate). The ROBINS-I was intended 
to completed by a panel of content and methodological experts related to the review75. The risk 
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of bias report generated by the single reviewer, was however evaluated by a senior member of 
the review team and no change in judgements were deemed necessary.  
This systematic review was limited by the scarcity of data on the effects of extended intervals 
longer than 6m on the immunogenicity, efficacy or effectiveness of two-dose HPVV schedule. 
Further, the studies of immunogenicity included in this review included only participants of ages 
9-14 years, so while our data will be relevant to the primary target group for HPV vaccination 
(females 9-14 years) and boys of that age, it may not be generalizable to older females.  
 
Implications and Recommendations for Public Health Practice 
The minimal immune correlates necessary for protection against HPV infection remains 
unknown, however, antibody response is an essential component of the protection against HPV 
infection. The findings of non-inferior immunogenicity for hrHPV types after extended dosing of 
the two-dose schedule are particularly encouraging for public health, and have implications for 
HPV schedule recommendations.   
First, the generally greater immunogenicity when the two-dose interval is 12m versus 6m 
suggests that 0,12m could safely be promoted as the preferred dosing interval in HPVV dose 
recommendations, rather than 0,6m. This is especially true if a 12m interval can truly deliver 
added benefits in ease or costs of vaccine administration to the primary target population 
(females 9-14 years). Most Canadian provinces, including British Columbia, currently use a 
0,6m two-dose schedule in their school-based HPV vaccination programs20. Moving to a 0,12m 
schedule would reduce the number of school visits that health-care professionals must make each 
year to administer this vaccine. This could potentially improve the cost-effectiveness of the HPV 
vaccination programs.  
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It is unlikely however, that a 0,12m schedule would provide substantial alleviation of the current 
shortfall in HPVV supplies. Suggestions have been made for the two-dose interval to be 
extended to 3-5 years between doses28. The non-inferiority of HPV16 and 18 at a 36-96m 
interval compared to a 6m interval suggests that a 3-5 year interval between doses may perform 
acceptably among the primary target population. Considering that the study providing data for 
the 36-96m interval is of sub-optimal rigor, further investigation of this interval is justified to 
confirm whether it is sufficiently protective against HPV infection and pre-cursors to cervical 
cancer.   
Conclusion 
The evidence indicates non-inferiority of 0, 12 month schedules to 0, 6m schedules in 
immunogenicity to all HPV types. Also the 0, 36-96m schedule is non-inferior to HPV6, 16, 18 
but not HPV11. These findings support the use of HPVVs in two-dose schedules with extended 
intervals of 12 months for females and males 9-14 years of age and provides vaccination 
programs more flexibility in regards to the time for administering the second immunization. The 
non-inferiority of 36-96m to 6m for HPV6, 16 and 18 is promising but needs further 
confirmation since these findings were obtained from observational data in a study with a small 
sample size and have low certainty. The data available did not allow assessment of the effect of 
the extended interval (0,7+m) on vaccine efficacy and effectiveness and underscores the need for 
further investigations with regard to the effectiveness of two-dose schedules with intervals longer 
than 6 and 12 months.  
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Appendix 2a: Risk of Bias Assessment for Gilca et al 2019 
Domain  Judgement Reason 
Bias due to confounding  Moderate 36-96m participants all vaccine non-compliant while 6m all compliant 
  HPV vaccination coverage lower among socially deprived individuals in Quebec 
  judgement reduced to moderate to reflect potential for indication bias 
   
Bias in selection of participants Moderate 36-96m participants are non-compliant vaccinees who consented to second dose  
  
no data provided on the proportion of those who consented or characteristics 
relative to those who did not 
  judgement reduced to moderate to reflect potential for volunteer bias 
   
Bias in classification  
of interventions Low only assessed HPV types present in both vaccines (HPV6,11,16,18) 
   
Bias due to deviations from  
intended interventions Low no deviation reported 
   
Bias due to missing data Low  no data of interest missing 
   
Bias in measurement of outcomes Low objective ELISA measurement so antibody level with defined cutoff for positive 
   
Bias in selection of the  
reported result Low none detected 
   
Overall Moderate Possibly favours 36-96m if HPV exposure higher in this group 
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Appendix 2b: Risk of Bias Assessment for Lamb et al 2017 
Domains  Judgement Reason 
   
Bias due to confounding  Moderate 
authors suggest potential for unknown confounder as 8+m AGW IR unexpectedly 
higher  
  10-16 years age group is inadequate to control for effect of age  
  age structure within 10-16 years group not compared for 8+m and 4-7m  
   
Bias in selection of participants Low all database entries meeting predefined selection criteria included 
   
Bias in classification of 
interventions Low intervention 8+m vs 4-7m defined and not amendable by knowledge of outcome 
   
Bias due to deviations from 
intended interventions Low no cointerventions 
   
Bias due to missing data Low  database lacks outcomes for undiagnosed or untreated participants 
  
both 8+m and 4-7m participants were vaccinated and expected to have similar 
likelihood of healthcare access 
   
Bias in measurement of 
outcomes Low outcome defined prior to identification in database records 
   
Bias in selection of the reported 
result Low IR reported for each pre-specified time-interval 
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Appendix 3: Table of GRADE assessment of the evidence in this systematic review 
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Appendix 4: Tables summarizing data used and relative effect measures generated 
 
Table: Summary Data Table 1 










Evidence   0, 7+m 0, 6 m 
HPV6 Seroconversion difference (%) at 1 month post-last-dose     




M:263/263 0.19% (-1.28, 1.08)* high 
4v then 9v (0,36-96m vs 0,6m) F & M 9-14 yrs 31, 173 31/31 173/173 0.00% (-11.07, 2.18) low 
  
 
    
 
 
HPV11 Seroconversion difference (%) at 1 month post-last-dose     




M:264/264 0.00% (-1.47, 0.73)* high 
4v then 9v (0,36-96m vs 0,6m) F & M 9-14 yrs 31, 173 31/31 173/173 0.00% (-11.07, 2.18) low 
2v= bivalent vaccine, 4v=quadrivalent vaccine, 9v= nonavalent vaccine, ATPP= according-to-protocol; population, F= female, 
















Table: Summary Data Table 2 
 
2v= bivalent vaccine, 4v=quadrivalent vaccine, 9v= nonavalent vaccine, ATPP= according-to-protocol; population, F= female, 










Reported Outcome Measure  
Effect estimate  
(95% CI) 
Certainty of 
Evidence   0, 7+m 0, 6 m 
  
 
    
HPV16 Seroconversion difference (%) at 1 month post-last-dose     
2v vaccine (0,12m vs 0,6m) F 9-14 yrs 339, 455 339/339 455/455 0.00% (-1.12, 0.84) high 






M:273/273 0.00% (-1.44, 0.70)*  
4v then 9v (0,36-96m vs 0,6m) F & M 9-14 yrs 31, 173 31/31 173/173 0.00% (-11.07, 2.18) low 
  
 
    
HPV16 Seropositivity difference (%)  at 6 months post-lastdose     
2v vaccine (0,12m vs 0,6m) F 9-14 yrs 339, 455 339/339 455/455 0.00% (-1.12, 0.84) high 
  
 
    
HPV16 Seropositivity difference (%) at 12 months post-last-dose     
2v vaccine (0,12m vs 0,6m) F 9-14 yrs 337, 453 337/337 453/453 0.00% (-1.13, 0.84) high 





Table: Summary Data Table 3 
2v= bivalent vaccine, 4v=quadrivalent vaccine, 9v= nonavalent vaccine, ATPP= according-to-protocol; population, F= female, 












Reported Outcome Measure  
Effect estimate  
(95% CI) 
Certainty of 
Evidence  0, 7+m 0, 6 m 
  
 
    
HPV18 Seroconversion difference (%) at 1 month post-last-dose      
2v vaccine (0,12m vs 0,6m) F 9-14 yrs 355, 462 355/355 455/462 1.52% (0.44, 3.10) high 





F: 272/272,  
M: 272/272  0.00% (-1.43, 0.70)*  
4v then 9v (0,36-96m vs 0,6m) F & M 9-14 yrs 31, 173 31/31 173/173 0.00% (-11.07, 2.18) low 
  
 
    
HPV18 Seropositivity difference (%) at 6 months post-last-dose      
2v vaccine (0,12m vs 0,6m) F 9-14 yrs 355, 462 355/355 455/462 1.52% (0.44, 3.10) high 
  
 
    
HPV18 Seropositivity difference (%) at 12 months post-last-dose      
2v vaccine (0,12m vs 0,6m) F 9-14 yrs 353, 459 353/353 453/459 1.31% (0.22, 2.82) high 
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Table: Summary Data Table 4 
2v= bivalent vaccine, 4v=quadrivalent vaccine, 9v= nonavalent vaccine, ATPP= according-to-protocol; population, F= female, 
M=male, *=based on pooling data for female and males as a single 0,6m group 
 
 






Reported Outcome Measure      
 
 
Effect estimate  
(95% CI).  Certainty of 
Evidence  0, 7+m 0, 6 m 
HPV31 Seroconversion difference (%) at 1 month post-last-dose      
9v vaccine (0,12m vs 0,6m) F & M 9-14 yrs 
 
268, 543 268/268 
F:271/272,  
M:271/271 0.18% (-1.23, 1.04)* high 
  
 
    
HPV33 Seroconversion difference (%) at 1 month post-last-dose      




M:271/271 0.18% (-1.23, 1.03)* high 
  
 
    
HPV45 Seroconversion difference (%) at 1 month post-last-dose      




M:271/273 0.73% (-0.69, 1.87)* high 
  
 
    
HPV52 Seroconversion difference (%) at 1 month post-last-dose      
9v vaccine (0,12m vs 0,6m) F & M 9-14 yrs 
268, 545 
268/268 
F: 271/272, M: 
273/273 0.18% (-1.23, 1.03)* high 
  
 
    
HPV58 Seroconversion difference (%) at 1 month post-last-dose      
9v vaccine (0,12m vs 0,6m) F & M 9-14 yrs 265, 540 265/265 
F:270/270, 
M:270/270 0.00% (-1.43, 0.71)* high 
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Table: Summary Data Table 5 




Reported Outcome Measure  Effect estimate  
(95% CI) 
Certainty of  
Evidence  0, 7+m 0, 6 m 
HPV6 Antibody Ratio at 1 month post-last-dose      
9v vaccine (0,12m vs 0,6m) 
F & M   
9-14 yrs 
257,  
258 + 263 
2678.8  
(2390.2, 3002.1) 
F:1657.9 (1479.6, 1857.6), 
M: 1557.4 (1391.5, 1743.1) 1.67 (1.49, 1.87)* high 
4v then 9v (0,36-96m vs 0,6m) 
 
F & M  
9-14 yrs 31, 173 
1640.5  
(1094.7, 2458.3) 1174.5 (1049.0, 1315.3) 1.40 (0.92, 2.13) low 
  
 
    
 
HPV11 Antibody Ratio at 1 month post-last-dose      
9v vaccine (0,12m vs 0,6m) 
F & M  
9-14 yrs 
257,  
258 + 264 
2941.8  
(2626.6, 3294.9) 
F: 1388.9 (1240.4, 1555.3),  
M: 1423.9 (1273.2, 1592.3) 2.09 (1.87, 2.34)* high 
4v then 9v (0,36-96m vs 0,6m) 
 
F & M  
9-14 yrs 31, 173 
374.7  
(246.6, 569.1) 593.9 (527.7, 668.3) 0.63 (0.41, 0.97) low 
2v= bivalent vaccine, 4v=quadrivalent vaccine, 9v= nonavalent vaccine, ATPP= according-to-protocol; population, F= female, 
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Table: Summary Data Table 6 







Reported Outcome Measure  Effect estimate  
(95% CI) 
Certainty of 
Evidence  0, 7+m 0, 6 m 
  
 
    
HPV16 Antibody Ratio at 1 month post-last-dose      






(8792.4, 10055.8) 1.20 (1.09, 1.33) high 
9v vaccine (0,12m vs 0,6m) 
F & M  
9-14 yrs 
264,  
272 + 264 
14329.3 
(12796.4, 16045.9) 
F: 8004.9 (7160.5, 8948.8),  
M: 8474.8 (7582.4, 
9472.3) 1.74 (1.55, 1.95)*  
4v then 9v (0,36-96m vs 0,6m) 
 
F & M  




(334.6, 422.2) 1.08 (0.71,1.63) low 
   
 
    
HPV16 Antibody Ratio at 6 months post-last-dose      






(2473.5, 2846.6) 1.22 (1.09, 1.37) high 
   
 
    
HPV16 Antibody Ratio at 12 months post-last-dose      






(1608.6, 1862.0) 1.27 (1.13, 1.42) high 
  
 
    
2v= bivalent vaccine, 4v=quadrivalent vaccine, 9v= nonavalent vaccine, ATPP= according-to-protocol; population, F= female, 
M=male, *=based on pooling data for female and males as a single 0,6m group 
 
 
Table: Summary Data Table 7 
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Reported Outcome Measure  




Evidence  0, 7+m 0, 6 m 
HPV18 Antibody Ratio at 1 month post-last-dose      





(6075.8, 7126.0) 5935.6 (5519.4, 6383.3) 1.11 (1.00, 1.23) high 
9v vaccine (0,12m vs 0,6m) F & M 9-14 yrs 
266,  
272 + 272  
2810.4  
(2474.9, 3191.3) 
F: 1872.8 (1651.6, 2123.6),  
M: 1860.9 (1641.1, 2110.2) 1.51 (1.33, 1.71)*  
4v then 9v (0,36-96m vs 0,6m) F & M 9-14 yrs 31, 173 
 
552.9  
(348.5, 877.2) 525.2 (470.1, 586.8) 1.05 (0.65, 1.69) low 
  
 
    
HPV18 Antibody Ratio at 6 months post-last-dose      




(1699.4, 2036.4) 1523.6 (1403.7, 1653.7) 1.22 (1.08, 1.38) high 
  
 
    
HPV18 Antibody Ratio at 12 months post-last-dose      




(1067.1, 1293.2) 864.6 (793.1, 942.7) 1.35 (1.19, 1.55) high 
  
 
    
2v= bivalent vaccine, 4v=quadrivalent vaccine, 9v= nonavalent vaccine, ATPP= according-to-protocol; population, F= female, 









Table: Summary Data Table 8 
 






Reported Outcome Measure 
Effect estimate 
(95% CI) 
Certainty of  
Evidence  0, 7+m 0, 6 m 
 
HPV31 Antibody Ratio at 1 month post-last-dose      
9v vaccine (0,12m vs 0,6m) 







F: 1436.3 (1272.1, 1621.8),  
M: 1498.2 (1326.5, 1692.0) 1.44 (1.28, 1.63)* high 
  
 
    
HPV33 Antibody Ratio at 1 month post-last-dose      
9v vaccine (0,12m vs 0,6m) 
F & M  
9-14 yrs 
269,  
273 + 271 
2197.5  
(1961.9, 2461.3) 
F: 1030.0 (920.4, 1152.7),  
M: 1040 (928.9, 1164.3) 2.12 (1.9, 2.38)* high 
  
 
    
HPV45 Antibody Ratio at 1 month post-last-dose      
9v vaccine (0,12m vs 0,6m) 
F & M  
9-14 yrs 
268,  
274 + 273 
417.7  
(365.9, 476.9) 
F: 357.6 (313.7, 407.6),  
M: 352.3 (309.0, 401.7) 1.18 (1.03, 1.34) high 
  
 
    
2v= bivalent vaccine, 4v=quadrivalent vaccine, 9v= nonavalent vaccine, ATPP= according-to-protocol; population, F= female, 
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Table: Summary Data Table 9 
 











Evidence  0, 7+m 0, 6 m 
  
 
    
HPV52 Antibody Ratio at 1 month post-last-dose      
9v vaccine (0,12m vs 0,6m) 






F: 581.1 (521.9, 647.1),  
M: 640.4 (575.2, 713) 1.84 (1.65, 2.05)* high 
  
 
    
 
HPV58 Antibody Ratio at 1 month post-last-dose      
9v vaccine (0,12m vs 0,6m) 
F & M  
9-14 yrs 
265, 
270 + 270 
2444.6  
(2185.2, 2734.9) 
F: 1251.2 (1119.6, 1398.4), 
M: 1325.7 (1186.2,1481.6) 1.90 (1.70, 2.12)* high 
  
 
    
 
Incidence rate difference of Anogenital warts     






(-12.11, 524.53)# low 










(-49.41, 946.64) #  
  
 
    
2v= bivalent vaccine, 4v=quadrivalent vaccine, 9v= nonavalent vaccine, ATPP= according-to-protocol; population, F= female, 
M=male, *=based on pooling data for female and males as a single 0,6m group, #= per 100,000 person-years 
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